Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study
Open Access
- 13 March 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (4) , 846-852
Abstract
Background: Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. The emergence of resistance to BDQ, a key drug in treating MDR-TB, poses significant threats to TB treatment effectiveness. Methods: The National Institute of Tuberculosis and Respiratory Diseases in Delhi and the Médecins Sans Frontières clinic in Mumbai provide BDQ, delamanid, and carbapenem-based regimens for patients with suspected or confirmed treatment failure. BDQ phenotypic drug-susceptibility testing (DST) was performed for all BDQ-exposed patients. Treatment regimens were individualized based on exposure history, comorbidities, drug interactions, prior adverse drug reactions, and DST results. Results: Of 117 BDQ-exposed patients from December 2020–December 2022, 42 (36%) exhibited a BDQ-resistant strain. Median (IQR) age was 24 (22–32) years, with 63 (54%) females and 94% with pulmonary TB. Patients with a BDQ-resistant strain were older (median age: 27 vs 23 years; P = .04), more likely to have lung cavities (risk ratio [RR]: 1.8; 95%-CI: 1.1–3.1; P = .02), and be resistant to clofazimine (RR: 2.3; 95%-CI: 1.5–3.6; P = .001). Overall, 102 patients initiated treatment. Patients with BDQ-resistance had higher risk of unfavorable outcomes compared with BDQ-susceptible patients (RR:2.1; 95%-CI: 1.5–2.8; P < .001). Overall, 87% (33/38) of patients with BDQ-resistance experienced unfavorable treatment outcomes: 15 (40%) died, 15 (40%) had treatment failure, and 3 (8%) were lost-to-follow-up. Conclusions: The study highlights a concerning rate of BDQ-resistance among previously treated patients, resulting in poor treatment outcomes. To prevent treatment failure, we recommend implementing BDQ-DST, developing affordable and accurate rapid tests for BDQ-resistance, and intensifying research and development efforts for newer TB drugs.Keywords
This publication has 14 references indexed in Scilit:
- Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosisJournal of Biosafety and Biosecurity, 2024
- Diagnostics to support the scaling up of shorter, safer tuberculosis regimensThe Lancet Microbe, 2023
- Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patientsJournal of Global Antimicrobial Resistance, 2023
- Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal studyThe Lancet Infectious Diseases, 2022
- Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic reviewJAC-Antimicrobial Resistance, 2022
- Implications of bedaquiline-resistant tuberculosisThe Lancet Infectious Diseases, 2022
- Cavitary tuberculosis: the gateway of disease transmissionThe Lancet Infectious Diseases, 2020
- Bedaquiline Resistance: Its Emergence, Mechanism, and PreventionClinical Infectious Diseases, 2017
- Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant TuberculosisAntimicrobial Agents and Chemotherapy, 2017
- Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ MiceACS Infectious Diseases, 2016